denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Bristol Myers Squibb, Constellation Pharmaceuticals, Inc., Incyte Corporation, and PharmaEssentia USA.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Biological, therapy sequence, Therapies, Combinations, Adverse Events, Clinically relevant
Hematology Disease Topics & Pathways:
Biological, therapy sequence, Therapies, Combinations, Adverse Events, Clinically relevant
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Disclosures:
Verstovsek: PharmaEssentia: Research Funding; ItalPharma: Research Funding; AstraZeneca: Research Funding; Blueprint Medicines Corp: Research Funding; NS Pharma: Research Funding; Roche: Research Funding; Promedior: Research Funding; CTI Biopharma Corp: Research Funding; Protagonist Therapeutics: Research Funding; Sierra Oncology: Consultancy, Research Funding; Incyte Corporation: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Gilead: Research Funding; Novartis: Consultancy, Research Funding; Genentech: Research Funding.
Speakers:
Alessandro Vannucchi, MD, University of Florence
,
Claire Harrison, DM, FRCPath, Guys and St Thomas NHS Trust
,
Raajit K. Rampal, MD, PhD, Clinical Director, Leukemia Service, Memorial Sloan Kettering Cancer Center
and
Ann Mullally, MD, Brigham and Women’s / Dana-Farber Cancer Center, Harvard Medical School
Disclosures:
Vannucchi: Blueprint: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees. Harrison: Celgene: Honoraria, Research Funding, Speakers Bureau; CTI Biopharma Corp: Honoraria, Speakers Bureau; Gilead Sciences: Honoraria, Speakers Bureau; Incyte Corporation: Speakers Bureau; Janssen: Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau; Shire: Honoraria, Speakers Bureau; AOP Orphan Pharmaceuticals: Honoraria; Promedior: Honoraria; Roche: Honoraria; Sierra Oncology: Honoraria. Rampal: Incyte: Consultancy, Research Funding; Celgene: Consultancy; Promedior: Consultancy; CTI Biopharma: Consultancy; Jazz Pharmaceuticals: Consultancy; Blueprint: Consultancy; Stemline: Consultancy, Research Funding; Constellation: Research Funding; Galecto: Consultancy; Abbvie: Consultancy; Pharmaessentia: Consultancy. Mullally: Janssen: Consultancy, Research Funding; Actuate Therapeutics: Research Funding.
Myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and myelofibrosis (MF) are hematologic cancers that require careful monitoring and treatment. The goals for patients include reduction of symptom burden and prevention of progression. In recent years, the discovery of mutations in the JAK2 and CALR genes has enabled a paradigm shift toward individualized risk stratification and treatment.
This live, educational webcast is designed to provide clinicians with the latest understanding of risk stratification and management of patients with PV and MF. This will include current and emerging use of targeted therapy and patient-specific adverse event management. These topics will be integrated into real-world case scenarios, where the panel of expert faculty will discuss best practices for managing MF and PV across the continuum of care. The overall goal of this program is to give participants the tools needed to make informed diagnostic and treatment decisions tailored to individual patients with MPNs.
See more of: Satellite Symposia